EP0891359A1 - Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant - Google Patents

Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant

Info

Publication number
EP0891359A1
EP0891359A1 EP97916395A EP97916395A EP0891359A1 EP 0891359 A1 EP0891359 A1 EP 0891359A1 EP 97916395 A EP97916395 A EP 97916395A EP 97916395 A EP97916395 A EP 97916395A EP 0891359 A1 EP0891359 A1 EP 0891359A1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
carboxylic acid
oxo
octahydro
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97916395A
Other languages
German (de)
English (en)
Inventor
Christos Tsaklakidis
Liesel Doerge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19612827A external-priority patent/DE19612827A1/de
Priority claimed from DE1996154479 external-priority patent/DE19654479A1/de
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Publication of EP0891359A1 publication Critical patent/EP0891359A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • oxazolidine derivatives effectively inhibit the aggregation of blood platelets and can therefore be used for the treatment of diseases which are attributable to thromboembolic events, such as stroke.
  • diseases which are attributable to thromboembolic events such as stroke.
  • the present invention relates to compounds of the general formula I
  • M represents oxygen, sulfur or NR 00 ,
  • X represents hydrogen or NR 1 R 2 ,
  • W denotes nitrogen or NH or CH or CH 7 ,
  • Y represents nitrogen or CH
  • Z is nitrogen, CH or C-OH
  • A denotes an optionally substituted alkylene chain - (CH 2 ) p -
  • n 1-3 means
  • R 1 , R 2 independently of one another are hydrogen, lower alkyl, aryl, arylalkyl, hetaryl, acyl or an optionally substituted carbocyclic or heterocyclic ring, or together with the nitrogen to which they are attached are an optionally substituted five- or six-membered ring which may also contain 1 to 3 further heteroatoms, or a group (c)
  • R 3 represents hydrogen or a group -OR 5 or -NR 6 R 7 ,
  • R 4 is hydrogen, lower alkyl, aryl, arylalkyl, hetaryl or a group -OR 5
  • R 5 denotes hydrogen, lower alkyl, aryl or arylalkyl
  • R 6 represents hydrogen, lower alkyl or arylalkyl
  • R 7 is hydrogen, lower alkyl, arylalkyl, acyl, alkylsulfonyl or arylsulfonyl
  • R 8 is hydrogen, methyl, ethyl, isopropyl, tert. -Butyl, phenyl or benzyl,
  • R 10 denotes hydrogen, lower alkyl, arylalkyl, acyl, alkylsulfonyl, arylsulfonyl or a group (c),
  • R 0 denotes hydrogen, lower alkyl, arylalkyl or a group -NHR 00 ,
  • R 00 is hydrogen, lower alkyl, arylalkyl, acyl, alkylsulfonyl or arylsulfonyl
  • Lower alkyl should in all cases be a straight-chain or branched C 1 -C 6 -alkyl group such as, for. B .. represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl, in particular methyl, ethyl, propyl, isobutyl and pentyl
  • Aryl generally means the optionally mono- or polysubstituted phenyl radical.
  • Hetaryl generally means an unsubstituted or mono- or polysubstituted pyridyl, pyrimidyl, piperazyl, imidazolyl, pyrrolyl, furyl or thiophenyl radical, preferably a pyridyl, pyrimidyl indolyl or imidazolyl radical.
  • Arylalkyl generally means an unsubstituted or mono- or polysubstituted benzyl, phenethyl, phenylpropyl, phenylbutyl or phenylpentyl radical, preferably a benzyl, phenethyl or phenylpentyl radical.
  • the substituents are C 1 -C 6 -alkyl radicals, preferably methyl, ethyl or isopropyl, and also chlorine, bromine, fluorine, or hydroxyl, methoxy, benzyloxy, acetyloxy, carboxy, ethoxycarbonyl, aminocarbonyl, , Methylaminocarbonyl, dimethylaminocarbonyl, cyano, amino, methylamino, dimethylamino, benzylamino, acetylamino, benzoylamino and amidino groups in question.
  • Acyl generally means the formyl, acetyl, propionyl, butyryl or benzoyl radical, in particular the acetyl or benzoyl radical.
  • Alkylsulfonyl generally means methanesulfonyl, ethanesulfonyl, propanesulfonyl or the butanesulfonyl radical, in particular the butanesulfonyl radical.
  • Arylsulfonyl usually means the benzene or toluenesulfonic acid residue.
  • Carboclyclic ring generally means a saturated or unsaturated 5-6-membered ring, optionally monosubstituted or disubstituted by lower alkyl, such as the cyclopentyl, cyclohexyl, cyclopentenyl or cyclohexenyl ring.
  • Heterocyclic ring generally means a saturated or unsaturated, 5-6-membered ring which is optionally monosubstituted or disubstituted by lower alkyl, such as the pyrolidine, piperidine, piperazine, morpholine, tetrahydropyrimidine, dihydropyridine or dihydroimidazole ring, preferably the piperidine or tetrahydropyrimidine ring.
  • the radicals R 1 and R 2 together with the nitrogen to which they are attached form a five- or six-membered ring, it is a saturated or unsaturated, optionally substituted by lower alkyl 5- or 5- membered ring, such as the pyrrolidine, piperidine.
  • Piperazine, morpholine, tetrahydropyrimidine, dihydropyridine, or dihydroimidazole ring preferably the piperidine, pyrrolidine or tetrahydropyrimidine ring.
  • the heterocyclic ring of the formula (a) generally represents the pyridine, pyridazine or pyrimidine ring, in particular the pyridine or pyrimidine ring.
  • the heterocyclic ring of the formula (b) generally represents the piperidine or hexahydropyrimidine ring, in particular the piperidine ring.
  • Compounds of the general formula I contain at least one asymmetric carbon atom, which is why optically active compounds of the general formula I are also the subject of the present application.
  • the present application furthermore relates to conformational isomers of compounds of the general formula I which can optionally occur.
  • X, Q, W and Y have the meanings given above;
  • L usually means a leaving group such as chlorine, bromine, iodine, mesylate, triflate or tosylate, in particular chlorine or tosylate.
  • R 4 , A, D, L and n have the meanings given above.
  • Compounds of the general formula VII can be prepared by reacting a compound of the general formula VI with an organometallic compound of the general formula XX prepared from a compound of the general formula VIII
  • a and n have the meanings given above and M has the meaning of a metal such as lithium, magnesium or titanium.
  • L 1 usually means the hydroxyl or acetyloxy group, or has one of the meanings of L.
  • R 1 1 usually means Methyl, ethyl, tert-butyl, phenyl or benzyl radical, in particular the tert-butyl or benzyl radical.
  • the compounds of the general formula XII are generally commercially available pipecoline carboxylic acid derivatives, in special cases compounds of the formula XII can be obtained by converting a commercially available 3- or 4-pperidone of the formula XXI,
  • R 3 , R 8 and m have the meanings given above.
  • R 9 means butyl, phenol or p-tolyl and shark - chloride, bromide or iodide.
  • Wittig reagents of the formula XXIII are partly commercially available and can be prepared from the corresponding commercially available halogen compounds and triphosphines.
  • the hydrolysis of an ester of the general formula I to the corresponding carboxylic acid of the general formula I is carried out by customary processes, in which a carboxylic acid ester of the general formula I is preferably in water or in a mixture of water, tetrahydrofuran, dioxane, methanol or ethanol a water / tetrahydrofuran mixture with a hydroxide such as sodium potassium, or lithium hydroxide, preferably sodium or lithium hydroxide, or with an acid such as hydrochloric acid, sulfuric acid or trifluoroacetic acid, preferably trifluoroacetic acid and at temperatures between room temperature and 80 ° C., preferably at Room temperature, treated.
  • a carboxylic acid ester of the general formula I is preferably in water or in a mixture of water, tetrahydrofur
  • reaction of a compound of general formula XIII with 1 -benzylp ⁇ peraz ⁇ n or 4-hydroxy- or 4-oxop ⁇ perid ⁇ n is generally carried out in one aprotic solvents such as toluene, tetrahydrofuran, diethyl ether, dimethylformamide or methylene chloride, preferably dimethylformamide or tetrahydrofuran using a base such as potassium hydride, sodium hydride, potassium carbonate or sodium hydrogen carbonate, preferably sodium hydride or potassium carbonate and at temperatures between room temperatures and 180 ° C. preferably at 120 ° C or room temperature.
  • aprotic solvents such as toluene, tetrahydrofuran, diethyl ether, dimethylformamide or methylene chloride, preferably dimethylformamide or tetrahydrofuran using a base such as potassium hydride, sodium hydride, potassium carbonate or sodium hydrogen carbonate, preferably sodium hydride or potassium carbonate and at
  • a ketone of the formula XVI with dibenzylamine or an amine of the formula XXV is carried out by processes known from the literature by reacting the ketone and amine component in a solvent such as methanoi or ethanol in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoborohydride with the addition of a Bronsted or Lewis acid such as hydrochloric acid, acetic acid, titanium tetrachloride or titanium tetraisopropylate and at a temperature between 0 ° and 100 ° C.
  • a solvent such as methanoi or ethanol
  • a reducing agent such as sodium cyanoborohydride or sodium triacetoborohydride
  • a Bronsted or Lewis acid such as hydrochloric acid, acetic acid, titanium tetrachloride or titanium tetraisopropylate and at a temperature between 0 ° and 100 ° C.
  • a hydrogenation catalyst such as platmdioxide and a hydrogen atom
  • a hydrogenation catalyst such as platmdioxide and a hydrogen atom
  • nitrosation of a compound of general formula XIV to a compound of formula XV is usually carried out with sodium nitrite or isoamyl nitrite in water or ethanol with the addition of an acid such as hydrochloric acid or acetic acid and at a temperature between -20 ° C. and 80 ° C., preferably at room temperature.
  • the reduction of a nitroso compound of the general formula XV is carried out by known processes in that a compound of the formula XV in a solvent such as water, acetic acid, ethanol, tetrahydrofuran or diethyl ether, preferably acetic acid or tetrahydrofuran with a reducing agent such as elemental zinc, lithium aluminum hydride or sodium aluminum hydride, preferably elemental zinc or lithium aluminum hydride and at a temperature between room temperature and 120 ° C., but preferably at 70 ° C.
  • a catalyst such as palladium / carbon (Hatt, HH, Org.
  • the Wittig reagents used are optionally prepared analogously to processes known from the literature (Buddras J., Angew. Chem. 80, 535 (1968), Bestmann HJ Angew Chem. 77, 620, 651 (1965); Wittig G. Ber. German. Chem. Ges 88, 1654 (1955)).
  • the Wittig reaction is carried out according to known methods by refluxing the reactants in an aprotic solvent such as benzene, toluene or xylene, preferably toluene.
  • an aprotic solvent such as benzene, toluene or xylene, preferably toluene.
  • Phthalimide hydrolysis is generally carried out by known processes by treating the phthalimide with hydrazine hydrate or semi-concentrated mineral acid such as hydrochloric acid or sulfuric acid, preferably with hydrazine hydrate or hydrochloric acid at room temperature.
  • the acylation of amines with an acylating agent is generally carried out in a solvent such as methylene chloride, dimethylformamide or pyridine, preferably methylene chloride or pyridine with the addition of an auxiliary base such as triethylamine or 4-dimethylaminopyridine and at a temperature between -10 ° C. and 50 ° C. but preferably at room temperature.
  • a solvent such as methylene chloride, dimethylformamide or pyridine, preferably methylene chloride or pyridine
  • an auxiliary base such as triethylamine or 4-dimethylaminopyridine
  • Suitable acylating agents are carboxylic acid halides such as acetyl chloride, propionide bromide or benzyloxycarbonyl chloride or carboxylic acid anhydrides such as acetic anhydride or di-tert-butyl dicarbonate, but preferably acetic anhydride, benzyloxycarbonyl chloride or di-tert-butyl dicarbonate.
  • the epoxidation of an olefin of the formula VII or of the formula X or of the formula VIII or of the formula XXVIII is carried out by processes which are known from the nature Reaction with a peracid such as m-chloroperbenzoic acid, peracetic acid or trifluoroperacetic acid, preferably m-chloroperbenzoic acid in an aprotic solvent such as methylene chloride and at a temperature between -30 ° C. and 50 ° C., preferably room temperature; Furthermore, the olefins mentioned above can be converted into the corresponding epoxides by means of the Sharpless epoxidation (Sharpless KB, Org. Syntheses, Vol 63, 66 (1985)).
  • the organometallic reaction mentioned in Scheme 3 is usually the Grignard reaction, which is carried out using methods known from the literature.
  • the magnesium reagent of the formula XX can optionally be converted into a lithium or titanium reagent before it is reacted with a carbonyl compound of the formula VI (Reetz M.T., Chem. Ber. 118, 1421 (1985)).
  • An amino alcohol of the formula III is converted into a compound of the formula 1 (Scheme 1) by processes known from the literature by reacting an amino alcohol of the formula III with diethyl carbonate (Evans D. A, Org. Syntheses, Vol. 68, 77 (1989)) or Carbonyidiimidazole (Chadwick D. I, J. Chem. Soc. Perkin Trans. 481 (1984), Geflfken D. Arch Pharm 313, 817 (1980)) or Phosgene (Newman WS. J Am Chem. Soc. 73, 4199 (1951 )) or Di- or Triphosen (Hassner A, Synth Commun 23, 2839 (1993)), or chloroformic acid methyl.
  • diethyl carbonate Evans D. A, Org. Syntheses, Vol. 68, 77 (1989)
  • Carbonyidiimidazole Chadwick D. I, J. Chem. Soc. Perkin Trans. 481 (19
  • a solvent such as methylene chloride , Dimethylformamide, toluene, xylene, ethanol, dioxane, tetrahydrofuran, water or diethyl ether, preferably dimethylformamide, methylene chloride, ethanol or
  • the catalytic hydrogenation of a compound of formula XXIV is carried out in a solvent such as methanol or ethanol with the addition of a catalyst such as ruthenium oxide, rhodium oxide or palladium / strontium carbonate, preferably rhodium oxide in a hydrogen atmosphere at a pressure of 1-200 bar, preferably at 200 bar and one Temperature between room temperature and 200 ° C. by (Rastin R H, 1 Chem.Soc. 1855 (1949).
  • a catalyst such as ruthenium oxide, rhodium oxide or palladium / strontium carbonate, preferably rhodium oxide in a hydrogen atmosphere at a pressure of 1-200 bar, preferably at 200 bar and one Temperature between room temperature and 200 ° C. by (Rastin R H, 1 Chem.Soc. 1855 (1949).
  • the epoxy opening of an epoxide of the formula V with an amine of the formula IV (Scheme 1) or an epoxide of the formula IX with an amine of the formula XII (Scheme 4) usually takes place in a solvent such as methanol, ethanol, dimethylformamide or toluene, preferably ethanol or toluene and at a temperature between 0 ° C. and 120 ° C. preferably 80 ° C. instead of.
  • a solvent such as methanol, ethanol, dimethylformamide or toluene, preferably ethanol or toluene and at a temperature between 0 ° C. and 120 ° C. preferably 80 ° C. instead of.
  • the epoxy opening of an epoxide of the formula V (scheme 1) with a metal azide is carried out according to methods known from the literature by reacting an epoxide of the formula V with a metal azide such as lithium, sodium, potassium, tributyltin or magnesium azide, preferably sodium azide, in a solvent such as Methanol ethanol 1, 4-dioxane, water, dimethylformamide tetrahydrofuran acetomtril or hexamethylphosphoric triamide, or in mixtures of the solvents mentioned, but preferably in methanol, dimethylformamide or 1,4-dioxane-water mixtures and at a reaction temperature between - 10 ° C. and 120 ° C. preferably 80 ° C.
  • a metal azide such as lithium, sodium, potassium, tributyltin or magnesium azide, preferably sodium azide
  • reaction of a compound of formula XXXI with a metal azide to a compound of formula XXVI represents, in the event that L 1 is L, a nucleophilic substitution which is carried out according to standard methods of organic synthesis.
  • the deacyiation of a compound of the formula XXX to a compound of the formula XXV is carried out by customary methods in which a compound of the formula XXX is in water or in a mixture of water.
  • Tetrahydrofuran, dioxane, methanol or ethanol preferably in a water / tetrahydrofuran mixture with a hydroxide such as sodium, potassium or lithium hydroxide, preferably sodium or lithium hydroxide, or with an acid such as hydrochloric acid, sulfuric acid or trifluoroacetic acid, preferably trifluoroacetic acid or with palladium / carbon
  • a hydroxide such as sodium, potassium or lithium hydroxide, preferably sodium or lithium hydroxide
  • an acid such as hydrochloric acid, sulfuric acid or trifluoroacetic acid, preferably trifluoroacetic acid or with palladium / carbon
  • Racemates of the formula I contain one or more chiral centers and can therefore be present in racemic or in optically active form. Racemates can be mechanically or chemically separated into the enantiomers by methods known per se.
  • the racemic mixture is preferably reacted with an optically active acid such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, almond acid, malic acid, lactic acid or the various optically active camphor sulfonic acids such as ß-camphor sulfonic acid diastereomers.
  • an optically active acid such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, almond acid, malic acid, lactic acid or the various optically active camphor sulfonic acids such as ß-camphor sulfonic acid diastereomers.
  • optically active compounds of the formula I by the methods described above, using starting materials (for example those of the formula V or VIII) which are already optically active.
  • prodrug forms of compounds of the general formula I are also claimed, but especially carboxylic acid esters of the general formula I in which R 8 is methyl, ethyl, n-propyl, isopropyl, butyl or phenyl - or benzyl radical means in particular the methyl, ethyl or benzyl radical.
  • salts especially alkali salts, ammonium salts, trifluoroacetates or hydrochlorides are used.
  • B. by titration of the compounds with inorganic or organic bases or acids such.
  • the salts are usually purified by falling over from water / acetone.
  • novel substances of the formula I according to the invention and their salts can be administered enterally or parenterally in liquid or solid form. All customary forms of administration, for example tablets, can be used here. Capsules, dragees, syrups, solutions, suspensions, etc. Water is preferably used as the injection medium, which contains the additives common to injection solutions such as stabilizers, solubilizers and buffers. Such additives are e.g. B. tartrate and citrate buffers, ethanol, complexing agents (such as ethylenediaminetetraacetic acid and their non-toxic salts), high molecular weight polymers (such as liquid polyethylene oxide) for viscosity control. Liquid carriers for injection solutions must be sterile and are preferably filled into ampoules.
  • Solid carriers are e.g. B. starch, lactose, mannitol, methyl cellulose, talc, highly disperse silica, high molecular weight fatty acids (such as stearic acid), gelatin, agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high molecular weight polymers (such as polyethylene glycols); Preparations suitable for oral administration can, if desired, contain flavorings and sweeteners.
  • the dosage can depend on various factors, such as the mode of administration and the species. Depend on age and / or individual condition.
  • the daily doses to be administered are approximately 1-1000 mg / person, preferably 100-500 mg / person, and can be taken in one or more times distributed.
  • (1R-2R-3S) -1-hydroxy-2,3-epoxycyclohexane can be isolated by epoxidation of the (R) -cyclohex-2-enol () Fukazawa et al, Tetrahedron Asymmetry 4, 2323 (1993)) by means of meta-chloroperbenzoic acid.
  • the title compound can be obtained by this process in better yield and higher purity than by process 1 h).
  • ⁇ NMR (d 6 -DMSO): ⁇ 8. 13 ppm (d, 2H); 7.25 (m, 2H); 7. 15 (m, 3H); 6.80 (d.
  • Microtiter plates were coated overnight with 2 ⁇ g / ml isolated activated GplIb / IIla receptor. After the unbound receptor was removed by a few washing steps, the surface of the plate was blocked with 1% casein and washed again. The test substance was added in the required concentrations, then the plates were incubated under rubble in a linear shaker for 10 minutes. The natural ligand of the gpIIb / IIIa receptor, fibronogen, was added.
  • the GpIIb / IIla fibrinogen ELISA is a modification of the assay described in the following references.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne de nouveaux dérivés de l'oxazolidine, des procédés permettant de les produire, ainsi que des médicaments les contenant. Elle concerne notamment des composés de formule générale (I), dans laquelle les symboles ont la signification mentionnée dans les revendications.
EP97916395A 1996-03-30 1997-03-26 Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant Ceased EP0891359A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19612827 1996-03-30
DE19612827A DE19612827A1 (de) 1996-03-30 1996-03-30 Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19654479 1996-12-27
DE1996154479 DE19654479A1 (de) 1996-12-27 1996-12-27 Neue Oxazolidinderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1997/001542 WO1997036899A1 (fr) 1996-03-30 1997-03-26 Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant

Publications (1)

Publication Number Publication Date
EP0891359A1 true EP0891359A1 (fr) 1999-01-20

Family

ID=26024325

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97916395A Ceased EP0891359A1 (fr) 1996-03-30 1997-03-26 Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant

Country Status (16)

Country Link
EP (1) EP0891359A1 (fr)
JP (1) JP2000510445A (fr)
KR (1) KR20000005117A (fr)
CN (1) CN1219933A (fr)
AR (1) AR006452A1 (fr)
AU (1) AU722747B2 (fr)
BR (1) BR9708475A (fr)
CA (1) CA2250250A1 (fr)
CZ (1) CZ305198A3 (fr)
HU (1) HUP9901741A3 (fr)
IL (1) IL126390A0 (fr)
NO (1) NO984547L (fr)
NZ (1) NZ332245A (fr)
PL (1) PL329053A1 (fr)
TR (1) TR199801961T2 (fr)
WO (1) WO1997036899A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2307899A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO2002074762A1 (fr) * 2001-03-15 2002-09-26 Takeda Chemical Industries, Ltd. Procede relatif a l'elaboration de derive sulfone
PT1379246E (pt) * 2001-04-18 2009-01-14 Euro Celtique Sa Análogos de nociceptina
JPWO2003095446A1 (ja) * 2002-05-09 2005-09-15 持田製薬株式会社 １−（４−ピリジル）−４−ピペリドンの製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9122016D0 (en) * 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds
WO1993010091A2 (fr) * 1991-11-14 1993-05-27 Glaxo Group Limited Derives de piperidine acide acetique utilises comme inhibiteurs de l'agregation des plaquettes hematiques dependante du fibrinogene
AU3351293A (en) * 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0623615B1 (fr) * 1993-05-01 1999-06-30 MERCK PATENT GmbH Dérivés de 1-phényl-oxazolidin-2-one substitués, leur préparation et leur utilisation comme antagonistes du récepteur d'adhésion
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9736899A1 *

Also Published As

Publication number Publication date
NO984547L (no) 1998-11-30
AU2505697A (en) 1997-10-22
CN1219933A (zh) 1999-06-16
AU722747B2 (en) 2000-08-10
PL329053A1 (en) 1999-03-01
KR20000005117A (ko) 2000-01-25
NO984547D0 (no) 1998-09-29
TR199801961T2 (xx) 1999-01-18
NZ332245A (en) 2000-03-27
IL126390A0 (en) 1999-05-09
WO1997036899A1 (fr) 1997-10-09
CA2250250A1 (fr) 1997-10-09
JP2000510445A (ja) 2000-08-15
CZ305198A3 (cs) 1999-02-17
BR9708475A (pt) 1999-04-13
AR006452A1 (es) 1999-08-25
HUP9901741A3 (en) 2000-03-28
HUP9901741A2 (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
RU2288913C2 (ru) Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4
WO1997003072A1 (fr) Derives nouveaux d'oxazolidinone, leur procede de preparation et medicaments contenant ces composes
DE69723104T2 (de) Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel
DE60221130T2 (de) 2 pyrrolidon-derivate als prostanoid-agonisten
DE60004504T2 (de) Tetrahydropyranderivate und deren verwendung als therapeutische mittel
EP2385040A1 (fr) Dérivés hétérocycliques renfermant de l'azote et médicaments contenant ces dérivés comme principe actif
WO1991013071A1 (fr) Nouveaux pyrroles trisubstitues, leur procede de fabrication, et medicaments renfermant ces composes
WO2002004402A1 (fr) Derives d'ester
WO1991013070A1 (fr) Nouveaux maleinimides trisubstitues, leur procede de fabrication, et medicaments renfermant ces composes
WO1997036899A1 (fr) Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant
DE4316117C2 (de) Cycloheptimidazol-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende, therapeutische Mittel
EP0000485A1 (fr) Pipéridino-propanols, leur préparation et compositions pharmaceutiques les contenant
EP0157324A2 (fr) Tétrahydrothiénopyridines, leur procédé de préparation et leur application comme médicaments
EP0034276A2 (fr) Dérivés phénylpipérazinyle de 1,3,4-oxadiazolylphénols, leur préparation et les compositions thérapeutiques les contenant
DE19654479A1 (de) Neue Oxazolidinderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19612827A1 (de) Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE102006039038A1 (de) Neues Herstellungsverfahren
WO2008092832A1 (fr) Procédé de production de d'hexafluorophosphates d'ammonium
EP0231744B1 (fr) Pyrrol-1-yl-phényl-dihydropyridazinones substituées, leur préparation et leur utilisation
DE3831162C2 (fr)
CH647497A5 (en) Process for the preparation of O-substituted hydroxylamines
DE2506155A1 (de) Oxigenierte azatetracyclen
EP0160256B1 (fr) Furanones condensées, leur procédé de préparation et leur application comme médicaments
EP0187122A2 (fr) Azacycloalkanes, azacycloalcènes 1,3,4-trisubstitués
WO1995000522A1 (fr) Derives d'acide phosphosuccinique et leur utilisation comme medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981030

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 981030;LV PAYMENT 981030;RO PAYMENT 981030;SI PAYMENT 981030

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS GMBH

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20010928